Sex effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson's disease

BMC Neuroscience

Table 3 the association between clinical feature and sex in LRRK2 G2385R carriers and non-carriers

	LRRK2 G2385R carriers		LRRK2 G2385R non-carriers		P-value (all female PD vs. all male PD)
	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p
EOPD	1.701 (0.508–5.693)	0.388	0.841 (0.563–1.256)	0.397	0.904 (0.618–1.321)	0.602
Advanced stage ^a	1.589 (0.222–11.353)	0.644	1.361 (0.824–2.248)	0.229	1.35 (0.838–2.184)	0.216
Impaired ADL ^a	0.599 (0.183–1.957)	0.392	0.610 (0.400–0.928)	0.021	0.617 (0.416–0.913)	0.016
Motor dysfunction ^a	0.750 (0.261–2.153)	0.592	0.695 (0.473–1.019)	0.063	0.698 (0.488–0.999)	0.049
Motor complication ^a	0.840 (0.201–3.513)	0.812	1.259 (0.720–2.199)	0.419	1.193 (0.714–1.995)	0.500
Cognitive impairment ^b	1.583 (0.458–5.477)	0.468	0.749 (0.485–1.156)	0.192	0.844 (0.564–1.264)	0.411
Sleep disorder ^c	2.006 (0.525–7.655)	0.309	1.358 (0.830–2.222)	0.223	1.417 (0.893–2.247)	0.139
Mood disorder ^c	0.854 (0.211–3.459)	0.825	1.691 (1.078–2.654)	0.022	1.594 (1.041–2.441)	0.032
olfaction ^c	1.850 (0.618–5.537)	0.271	0.686 (0.463–1.016)	0.060	0.774 (0.536–1.116)	0.170
RBD ^c	1.558 (0.575–4.218)	0.383	1.224 (0.823–1.821)	0.317	1.278 (0.885–1.844)	0.190
Autonomic dysfunction ^c	0.294 (0.102–0.849)	0.024	0.626 (0.428–0.917)	0.016	0.574 (0.402–0.820)	0.002
EDS ^c	1.095 (0.383–3.125)	0.866	0.555 (0.361–0.853)	0.007	0.619 (0.417–0.919)	0.017
Life quality ^c	1.024 (0.394–2.644)	0.961	1.054 (0.722–1.537)	0.786	1.003 (0.986–1.019)	0.764
SN + ^c	0.980 (0.149–6.443)	0.983	0.448 (0.228–0.878)	0.019	0.488 (0.260–0.919)	0.026

ISSN: 1471-2202